Crinetics Pharmaceuticals has filed a patent for compounds that act as parathyroid hormone (PTH) receptor modulators. The patent includes methods of making these compounds, pharmaceutical compositions containing them, and their use in treating conditions that would benefit from PTH receptor activity modulation. GlobalData’s report on Crinetics Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Crinetics Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Crinetics Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230159532A1) describes a compound of Formula (I'), along with its pharmaceutically acceptable salt or solvate. The compound, as claimed in the patent, has the structure of Formula (Ia) and can be used for treating diseases or conditions that require the modulation of parathyroid hormone (PTH) receptor activity.
The patent claims specify various variations of the compound, including different substitutions and configurations. For example, claim 8 states that the compound can have R1 as C1-6alkyl, which may or may not be substituted with one to five R19 groups. Claim 12 specifies that R1 can also be an unsubstituted C1-6alkyl. Similarly, claim 32 mentions that R2a and R2b can form a C2-9heterocycloalkyl, which may or may not be substituted with one to five R20 groups.
Furthermore, the patent claims also describe the possible substitutions for other groups in the compound. For instance, claim 36 states that each R3 can be independently selected from halogen, while claim 38 mentions that R5 can be selected from hydrogen, halogen, C1-6alkyl, C3-6cycloalkyl, C2-9heterocycloalkyl, —CN, —C(O)N(R12)(R13), and —OR12. Claim 42 specifies that R7 can be selected from hydrogen, halogen, C1-6alkyl, —CN, and —OR12, and claim 45 states that R9 can be selected from hydrogen, halogen, C1-6alkyl, C3-6cycloalkyl, —CN, and —OR12.
The patent also includes a method of treating a disease or condition in a mammal that requires the modulation of PTH receptor activity. This method involves administering the compound described in claim 1, or its pharmaceutically acceptable salt or solvate, to the mammal in need of treatment.
In summary, the filed patent describes a compound of Formula (I') and its various variations, along with their pharmaceutically acceptable salt or solvate. The compound can be used for treating diseases or conditions that require the modulation of PTH receptor activity. The patent also includes a method of administering the compound for therapeutic purposes.
To know more about GlobalData’s detailed insights on Crinetics Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
